Prelude Therapeutics (PRLD) and Lilly (LLY) Stock News: Trial Collaboration Pairs an Experimental Degrader With Two Lilly Drugs

Prelude Therapeutics announced on October 13 a clinical trial collaboration and supply agreement with Eli Lilly, according to the company’s announcement.

The deal#

Lilly will supply its CDK4/6 inhibitor abemaciclib, sold as Verzenio, and its oral estrogen receptor degrader imlunestrant, sold as Inluriyo, for a Phase 1 trial combining each with Prelude’s PRT13722, an oral degrader of the KAT6A protein. Prelude retains full global development and commercial rights to PRT13722. No payments were disclosed.

The trial#

The FDA has cleared the study under Prelude’s investigational new drug application. Enrollment is expected to begin in the fourth quarter of 2026 with single-agent dose escalation, followed by combination cohorts in patients with hormone receptor-positive, HER2-negative breast cancer. The company cites preclinical work showing activity alone and in combination with both drug classes; there are no human data on efficacy or safety yet.

What to compare next#

For readers following PRLD, a supply agreement with a large pharmaceutical company validates the trial design but is not a licensing deal, and the company’s cash runway remains the first question for a small biotech entering a multi-arm study. For LLY, supplying drugs to a partner’s trial is routine and immaterial to results; the interest is whether a new combination extends the useful life of its breast cancer franchise.

Published October 21, 2026. Informational reporting, not investment advice. Figures come from the company's own release unless stated; forward-looking guidance is management's current forecast and can change.